WO2004065392A8 - Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands - Google Patents

Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands

Info

Publication number
WO2004065392A8
WO2004065392A8 PCT/EP2004/000650 EP2004000650W WO2004065392A8 WO 2004065392 A8 WO2004065392 A8 WO 2004065392A8 EP 2004000650 W EP2004000650 W EP 2004000650W WO 2004065392 A8 WO2004065392 A8 WO 2004065392A8
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidines
alk
receptor ligands
therapy
condensed pyridines
Prior art date
Application number
PCT/EP2004/000650
Other languages
French (fr)
Other versions
WO2004065392A1 (en
Inventor
Nerina Dodic
Francoise Jeanne Gellibert
Robert Neil Hunter Iii
Original Assignee
Smithkline Beecham Corp
Nerina Dodic
Francoise Jeanne Gellibert
Robert Neil Hunter Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0301719A external-priority patent/GB0301719D0/en
Priority claimed from GB0308706A external-priority patent/GB0308706D0/en
Priority claimed from GB0315519A external-priority patent/GB0315519D0/en
Application filed by Smithkline Beecham Corp, Nerina Dodic, Francoise Jeanne Gellibert, Robert Neil Hunter Iii filed Critical Smithkline Beecham Corp
Publication of WO2004065392A1 publication Critical patent/WO2004065392A1/en
Publication of WO2004065392A8 publication Critical patent/WO2004065392A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Therapeutically active substituted quinoline and quinazoline compounds derivatives of formula (I) wherein X is N or CH, Y is NH, N (alkyl) or NH-CH2, and R2 and R3 are specified heterorings, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor β (TGF-β), and pharmaceutical compositions for use in such therapy are disclosed.
PCT/EP2004/000650 2003-01-24 2004-01-26 Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands WO2004065392A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0301719.1 2003-01-24
GB0301719A GB0301719D0 (en) 2003-01-24 2003-01-24 Compounds
GB0308706A GB0308706D0 (en) 2003-04-15 2003-04-15 Novel compounds
GB0308706.1 2003-04-15
GB0315519A GB0315519D0 (en) 2003-07-02 2003-07-02 Novel compounds
GB0315519.9 2003-07-02

Publications (2)

Publication Number Publication Date
WO2004065392A1 WO2004065392A1 (en) 2004-08-05
WO2004065392A8 true WO2004065392A8 (en) 2004-10-07

Family

ID=32776625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000650 WO2004065392A1 (en) 2003-01-24 2004-01-26 Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands

Country Status (1)

Country Link
WO (1) WO2004065392A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223766B2 (en) * 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
CA2520323C (en) * 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
GB0326963D0 (en) * 2003-11-19 2003-12-24 Glaxo Group Ltd Compounds
WO2006035061A1 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP4966958B2 (en) * 2005-03-14 2012-07-04 ノイロサーチ アクティーゼルスカブ Potassium channel modulators and medical use
WO2006100310A1 (en) 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Heterobicylic inhibitors of hcv
AR056347A1 (en) 2005-05-12 2007-10-03 Tibotec Pharm Ltd USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS
WO2007011759A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
CN101384591A (en) * 2005-12-21 2009-03-11 艾博特公司 Anti-viral compounds
CN102702194A (en) 2005-12-21 2012-10-03 雅培制药有限公司 Anti-viral compounds
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
CA2652341A1 (en) * 2006-05-15 2007-11-22 Senex Biotechnology, Inc. Identification of cdki pathway inhibitors
EP1878733A1 (en) * 2006-07-14 2008-01-16 Novartis AG Pyrimidine derivatives as ALK-5 inhibitors
AU2007271964B2 (en) 2006-07-14 2012-01-19 Novartis Ag Pyrimidine derivatives as ALK-5 inhibitors
WO2008009077A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
WO2008009078A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
JP4937666B2 (en) * 2006-08-01 2012-05-23 東ソー株式会社 2-trifluoromethylquinolines and process for producing the same
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
AR070127A1 (en) * 2008-01-11 2010-03-17 Novartis Ag PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
CN101531638B (en) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 Compound used as a regulator of estrogen-related receptor and applications thereof
RU2520098C2 (en) 2008-06-26 2014-06-20 Ресверлоджикс Корп. Method of producing quinazolinone derivatives
JP5635535B2 (en) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション Compounds for the prevention and treatment of cardiovascular disease
CA2992231C (en) 2009-03-18 2022-03-29 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
KR20190091564A (en) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
MX2011012581A (en) * 2009-05-29 2012-01-30 Syngenta Participations Ag Substituted quinazolines as fungicides.
KR20120079111A (en) * 2009-09-24 2012-07-11 에프. 호프만-라 로슈 아게 Heterocyclic antiviral compounds
CN102596200A (en) * 2009-11-07 2012-07-18 默克专利有限公司 Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
AR079814A1 (en) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd HETEROCICLICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES
WO2011104183A1 (en) * 2010-02-24 2011-09-01 Syngenta Participations Ag Novel microbicides
US9073918B2 (en) 2010-05-20 2015-07-07 Takeda Pharmaceutical Company Limited Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
WO2012079079A1 (en) * 2010-12-10 2012-06-14 President And Fellows Of Harvard College Production of induced pluripotent stem cells
KR20140048216A (en) * 2011-06-29 2014-04-23 오츠카 세이야쿠 가부시키가이샤 Quinazolines as therapeutic compounds and related methods of use
JP6121658B2 (en) * 2011-06-29 2017-04-26 大塚製薬株式会社 Therapeutic compounds and related methods of use
CN103945848B (en) 2011-11-01 2016-09-07 雷斯韦洛吉克斯公司 The oral immediate release formulations of the quinazolinone being replaced
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
JP2016506944A (en) 2013-02-01 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Substituted pyrazolopyrimidinylamino-indazole
SI3089971T1 (en) 2014-01-01 2020-11-30 Medivation Technologies Llc Compounds and methods of use
CA2978188C (en) 2015-03-04 2020-05-12 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
KR102662814B1 (en) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 Compositions and treatment methods for treating complement-related diseases
EP3325484A1 (en) * 2015-07-23 2018-05-30 Bristol-Myers Squibb Company Tgf beta receptor antagonists
BR112018012914B1 (en) 2015-12-22 2023-04-18 SHY Therapeutics LLC COMPOUND, USE OF A COMPOUND AND PHARMACEUTICAL COMPOSITION
WO2018045144A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
JOP20190257A1 (en) 2017-04-28 2019-10-28 Novartis Ag 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
SG11201911929XA (en) 2017-06-21 2020-01-30 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN112566906A (en) 2018-07-26 2021-03-26 多曼治疗学公司 Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4
CN109503550B (en) * 2018-11-20 2022-11-29 江西师范大学 2-azaaryl-6-substituted amino quinazolinone compound and preparation method and application thereof
EP3887364A1 (en) * 2018-11-30 2021-10-06 Celularity Inc. Aromatic compounds for use in activating hematopoietic stem and progenitor cells
TW202212339A (en) 2019-04-17 2022-04-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202210480A (en) 2019-04-17 2022-03-16 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202115056A (en) 2019-06-28 2021-04-16 美商基利科學股份有限公司 Processes for preparing toll-like receptor modulator compounds
JP2023509760A (en) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド ALK5 inhibitor complexes and uses thereof
CN113620956B (en) * 2020-05-06 2023-06-13 赛诺哈勃药业（成都）有限公司 Transforming growth factor receptor antagonist, preparation method and application thereof
CN113698395B (en) * 2020-05-22 2023-12-08 赛诺哈勃药业（成都）有限公司 Transforming growth factor receptor antagonist, preparation method and application thereof
EP4284377A1 (en) * 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
US20240309015A1 (en) * 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
WO2004065392A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2004065392A8 (en) Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
WO2005018557A3 (en) Substituted pyridinones
WO2000021926A3 (en) 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
SG179430A1 (en) Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
EA200400466A1 (en) DERIVATIVES OF PIPERAZINE WITH ANTAGONISTIC ACTIVITY TO CCR1 RECEPTOR
MXPA03000428A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives.
WO2004087677A3 (en) Pyrimidin-4-one derivatives and their use as p38 kinase modulators
ATE370138T1 (en) NEW IMIDAZOPYRIDINES AND THEIR USE
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
NO20084496L (en) Pyridyl and pyrimidinyl substituted pyrrole, thiophene and furan derivatives as kinase inhibitors
WO2007058832A3 (en) Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
MX337817B (en) PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES.
WO2002062794A3 (en) Compounds
NZ604345A (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
WO2005037836A3 (en) Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
WO2006065590A3 (en) Pyridine and pyrimidine antiviral compositions
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
MX2010006748A (en) PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS.
WO2003087088A3 (en) (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them
WO2008068507A3 (en) 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
NO20080418L (en) Pyrido [2,3-D] pyrimidiride derivatives, process for their preparation and therapeutic use of the same
WO2007110340A3 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN GAZETTE 28/2004 UNDER (30) REPLACE "20 NOVEMBER 2002 (20.11.2002)" BY "21 NOVEMBER 2002 (21.11.2002)"

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase